Magnesium Isoglycyrrhizinate OD
Phase 2Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Magnesium Isoglycyrrhizinate OD is one of 11 small molecule programs targeting Drug-Induced Liver Injury. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Drug-Induced Liver Injury
#DrugCompanyPhaseTrials
1Actigall
AbbVieApproved
Cellcept
RocheApproved
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Approved
Rayos
RRoxane Laboratories
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
N-Acetyl Cyteien
SStanford University
Phase 3
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Phase 2
High Volume Plasma Exchange
IInstitute of Liver and Biliary Sciences, India
Phase 3
Thiola Ec
MMission Pharmacal
Phase 2
Augmentin
TevaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details